Senthil Sundaram - Feb 1, 2023 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
Chief Executive Officer, Director
Signature
/s/ Bryan Yoon, as Attorney-in-Fact for Senthil Sundaram
Stock symbol
TERN
Transactions as of
Feb 1, 2023
Transactions value $
$4
Form type
4
Date filed
2/3/2023, 05:00 PM
Previous filing
Jun 8, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TERN Common Stock Purchase $4.23 +3 +0.04% $1.41* 7.66K Nov 30, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TERN Stock Option (Right to Buy) Award $0 +900K $0.00 900K Feb 1, 2023 Common Stock 900K $8.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes the purchase of 3 shares under the Terns Employee Stock Purchase Plan on November 30, 2022.
F2 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Includes voluntary reporting of ESPP purchase